Want to see MXCT full AI Analyst Report?
MXCT Stock Chart & Stats
$1.05
$0.02(2.38%)
At close: 4:00 PM EDT
$1.05
$0.02(2.38%)
Day’s Range― - ―
52-Week Range$0.64 - $2.19
Previous Close$1.05
Volume204.15K
Average Volume (3M)N/A
Market Cap
$112.48M
Enterprise Value-$14.29
Total Cash (Recent Filing)$14.56M
Total Debt (Recent Filing)$17.49M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Aug 12, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding107,121,670
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.48
Price to Book (P/B)0.96
Price to Sales (P/S)4.99
P/FCF Ratio-4.56
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$4.00Price Target Upside280.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.28
Revenue Forecast (FY)$31.09M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsMaxCyte’s proprietary electroporation platform and consumables produce persistently high gross margins. This durable margin profile gives scope for operating leverage as the installed base and SPL royalties scale, supporting long-term margin sustainability and profitability potential.
Strong Liquidity And Low LeverageA cash-rich, debt-free balance sheet provides substantial runway to fund commercialization (ExPERT DTx, SeQure), sustain operating plans while revenues recover, and optionality for strategic investments or milestone pursuits without immediate refinancing, materially lowering funding risk.
Robust SPL Partner PipelineA sizable SPL partner roster and milestone pipeline create structural, capital-light upside through licensing, milestones and royalties. Such program-based revenue diversifies reliance on instrument sales and can produce high-margin, long-dated cash flows as partners advance clinical programs.
Bears Say
Persistent Cash BurnDespite strong cash today, consistent negative operating and free cash flow indicates sustained cash burn. If core revenue recovery lags, MaxCyte may need to raise capital, diluting shareholders or constraining growth investments, increasing medium-term funding and execution risk.
Declining Core Revenue And DemandA sharp drop in core revenue and consumables points to weakening end-market demand and concentration risk from major customers. Reduced consumables usage undermines the recurring revenue base that underpins margins and long-term cash generation, limiting durable topline growth visibility.
Sustained UnprofitabilityThe company continues to operate at large losses despite high gross margins, producing negative ROE and shrinking equity. Continued unprofitability risks eroding shareholder capital and restricts reinvestment capacity until structural revenue recovery or sustained SPL milestone/royalty inflows occur.
MaxCyte News
MXCT FAQ
What was MaxCyte, Inc.’s price range in the past 12 months?
MaxCyte, Inc. lowest stock price was $0.64 and its highest was $2.19 in the past 12 months.
What is MaxCyte, Inc.’s market cap?
MaxCyte, Inc.’s market cap is $112.48M.
When is MaxCyte, Inc.’s upcoming earnings report date?
MaxCyte, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 8 days.
How were MaxCyte, Inc.’s earnings last quarter?
MaxCyte, Inc. released its earnings results on May 12, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.076 by $0.036.
Is MaxCyte, Inc. overvalued?
According to Wall Street analysts MaxCyte, Inc.’s price is currently Undervalued.
Does MaxCyte, Inc. pay dividends?
MaxCyte, Inc. does not currently pay dividends.
What is MaxCyte, Inc.’s EPS estimate?
MaxCyte, Inc.’s EPS estimate is -0.09.
How many shares outstanding does MaxCyte, Inc. have?
MaxCyte, Inc. has 107,121,670 shares outstanding.
What happened to MaxCyte, Inc.’s price movement after its last earnings report?
MaxCyte, Inc. reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.076. Following the earnings report the stock price went up 24.088%.
Which hedge fund is a major shareholder of MaxCyte, Inc.?
Currently, no hedge funds are holding shares in MXCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MaxCyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.00 (280.95% Upside)
$4.00 (280.95% Upside)
Hedge Fund Trend
Decreased
By 15.5K Shares
Last Quarter.
Last Quarter.
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.43%
Trailing 12-Months
Company Description
MaxCyte, Inc.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
MXCT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced clear operational and strategic positives — including a strong cash position, meaningful OpEx reductions, a $3.0M SPL milestone in Q1, early product traction (ExPERT DTX and SeQure), and a $10M share repurchase authorization — against near-term commercial headwinds, notably a 25% decline in core revenue and weaker PA and license receipts driven by customer inventory management and discontinued programs. Management reiterated full-year guidance while taking a conservative stance on additional 2026 milestones; they emphasized stability in the late-stage cell and gene therapy market, confidence in the pipeline, and expectations for core revenue growth later in the year. Overall, the results reflect transitionary near-term pressure but solid financial flexibility and promising product/partner catalysts that could drive recovery and growth over the medium term.View all MXCT earnings summariesMXCT Stock 12 Month Forecast
Average Price Target
$4.00
▲(280.95% Upside)
Ownership Overview
3.01% Insiders
10.47% Mutual Funds
11.01% Other Institutional Investors
71.55% Public Companies and
Individual Investors